ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

Servier’s $1.8bn Agios deal delivers glioma prospect

Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncolog

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Merck KGaA offloads failed MEK programme to startup Day One

US biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s pipeline for years, in the hope of giving it a new lease of life. 

Agios up as FDA gives Thermo Fisher glioma test breakthrough...

Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.

Tocagen plummets on phase 3 data for glioma therapy